Tongling Bionic Technology, specializing in providing lifecycle solutions for heart failure, will offer innovative Chinese products to patients with heart failure by continuing the technical innovation and accelerating the product process.
Tongling
Tongling Bionic Technology (Chinese: 通灵仿生) announced its completion of the Series B round of financing worth more than CNY 100 million recently. This round was led by Songyuan Funding (Chinese: 松源基金) which belonged to WEGO Group (Chinese: 威高集团).
The funding will be used to accelerate the research and development of products and the construction of factories.
Founded in 2016, Tongling is a high-tech company dedicated to providing the world's leading integrated solution for treating patients with heart failure. The company started the R&D work for Percutaneous ventricular assist devices (PVAD) in the country in 2017 and finished the typing test of miniature heart catheter pumps. Moreover, the company developed innovative products suitable for patients with heart failure, such as intra-aortic balloon pump (IABP), extracorporeal counterpulsation therapy systems, non-invasive cardiac output monitor and extracorporeal membrane oxygenation (ECMO) systems.
The company's competitors include magAssist (Chinese: 心擎医疗), CH Biomedical (Chinese: 同心医疗) and Venus Medtech (Chinese: 启明医疗).
The Billion-Dollar European Caviar Business, Now Disrupted by China
Nov 08, 2024 01:52 PM
Forty Years of Striving: How Globalization Has Shaped Lenovo Today?
Nov 07, 2024 06:51 PM